Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Indian Patients With Psoriatic Arthritis
NCT07141004Phase 4Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of guselkumab in psoriatic arthritis (PsA), sponsored by Johnson & Johnson. Started Aug 2025; status: recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07141004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141004.